share_log

Decoding 7 Analyst Evaluations For United Therapeutics

Decoding 7 Analyst Evaluations For United Therapeutics

解讀7位分析師對美國聯合醫療的評估
Benzinga ·  10/22 03:00
Throughout the last three months, 7 analysts have evaluated United Therapeutics (NASDAQ:UTHR), offering a diverse set of opinions from bullish to bearish.
在過去的三個月中,有7位分析師對美國聯合醫療(納斯達克:UTHR)進行了評估,提供了從看好到看淡的多樣觀點。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
以下表格總結了分析師們最近的評級,揭示了過去30天內情緒的變化並將其與前幾個月進行了比較。
Analysts have set 12-month price targets for United Therapeutics, revealing an average target of $409.57, a high estimate of $575.00, and a low estimate of $280.00. This upward trend is evident, with the current average reflecting a 18.57% increase from the previous average price target of $345.43.
分析師們爲美國聯合醫療設定了12個月的價格目標,顯示出平均目標爲409.57美元,最高預估爲575.00美元,最低預估爲280.00美元。這種上升趨勢是明顯的,當前平均數反映出與之前的345.43美元的平均價格目標相比增長了18.57%。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析師評級:詳細剖析
A comprehensive examination of how financial...
對金融專家如...

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論